Biomarin R&D day: massive patient-to-patient variability for Hemo A | SGMO Message Board Posts

Sangamo Therapeutics, Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  136572 of 138539  at  11/17/2019 4:43:50 PM  by

civic08801


 In response to msg 136567 by  spaddy
view thread

Re: Biomarin R&D day: massive patient-to-patient variability for Hemo A

The FDA recently rejected a number of Type I diabetes drugs in the same class from a number of Pharma because the agency was not satisfied with the adverse effects profile.

The FDA does not operate in a Vacuum . The FDA knows about the $GMO Hemo A trial.

Think About It, Very Quickly


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 204
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
136573 Re: Biomarin R&D day: massive patient-to-patient variability for Hemo A spaddy 14 11/17/2019 4:57:24 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...